Chronic Kidney Disease Registry Platform Study

Exclusion Criteria

• Registry Platform Study Basic Inclusion &
• Inclusion Criteria:
• (1) Aged ≥ 18 years at enrollment;
• (2) Patients who meet the diagnostic criteria for CKD;
• (3) Last eGFR ≥ 20 and < 90 mL/min/1.73 m2 (with the CKD-EPI formula) within 12 months prior to enrollment;
• (4) Patients who voluntarily participate in this study and has signed and dated the informed consent form for the study;
• Exclusion Criteria:
• (1) Patients who have previously undergone/are undergoing/are planning to undergo solid organ transplantation;
• (2) Patients with active malignant tumor requiring drug therapy at the time of screening;
• (3) Women who are pregnant, planning to become pregnant or who are breastfeeding.
• Group A (Participants with CKD and High Proteinuria) Inclusion & Exclusion Criteria:
• Inclusion criteria:
• Last documented proteinuria test within 12 months prior to enrollment indicating UACR ≥ 700 mg/g, or UPCR ≥ 1000 mg/g, or 24 h urine protein (quantitative) ≥ 1 g/24 h.
• Exclusion criteria:
• (1) Patients with NYHA class III or IV heart failure at screening;
• (2) Patients who have had myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), or undergone cardiac surgery, percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), valvular repair/replacement, or received treatment with left ventricular assist device within 3 months prior to screening;
• (3) Patients undergoing renal replacement therapy (RRT) at screening;
• (4) Patients on systemic immunosuppression at screening (inhalation, intranasal administration, or topical steroids are allowed) except for stable maintenance therapy. The stable maintenance therapy means treatment at least 3 months with Prednisone 10mg/day or lower (or equivalent dose of other drugs), Azathioprine 100mg/day or lower, or Mycophenolate mofetil 1000mg/day or lower (or equivalent dose of other drugs);
• (5) Patients with a life expectancy of less than 1 year, as judged by the investigator;
• (6) Patients who have participated in another interventional clinical trial and have received the investigational drug within 1 month prior to being enrolled.
• Group B (patients with CKD and Hypertension) Inclusion & Exclusion Criteria:
• Inclusion criteria:
• (1) Last documented test within 12 months prior to enrollment indicating UACR>200 mg/g（22.6 mg/mmol）and <5000 mg/g（565 mg/mmol）, or UPCR >500 mg/g and <8000 mg/g, or 24 h urine protein (quantitative) >0.5 g/24 h and <8 g/24 h;
• (2) Patients with hypertension history and Systolic Blood Pressure ≥130 mmHg at screening;
• Exclusion criteria:
• (1) Patients with NYHA class IV heart failure at screening;
• (2) Patients who have had stroke, transient ischemic attack (TIA), Carotid artery surgery or carotid angioplasty and stenting, acute Coronary Syndrome, or hospitalization caused by heart failure deterioration within 3 months prior to screening;
• (3) Patients who have known severe hepatic injury (defined as Child-Pugh class C) based on medical history;
• (4) Patients undergoing renal replacement therapy (RRT) within 12 weeks prior to screening;
• (5) Patients on systemic immunosuppression prior to screening (inhalation, intranasal administration, or topical steroids are allowed) except for stable maintenance therapy at least 3 months;
• (6) Patients with a life expectancy of less than 1 year, as judged by the investigator;
• (7) Patients who have participated in another interventional clinical trial and have received the investigational drug within 1 months prior to being enrolled.